Advertisement China Sky One Medical develops nasal spray for rheumatic disease - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

China Sky One Medical develops nasal spray for rheumatic disease

China Sky One Medical, a fully integrated pharmaceutical company producing external use, over-the-counter drugs in the People's Republic of China, has developed a nasal spray for the treatment and prevention of rheumatic disease.

Heilongjiang Tianlong Pharmaceutical, a wholly-owned subsidiary of China Sky One Medical has recently completed R&D for the spray, which includes the active ingredients naphazoline hydrochloride chlorpheniramine maleate and benzalkonium bromide.

There are currently only five other manufacturers of the spray in China and China Sky One has obtained the necessary approvals for production.

Yan-Qing Liu, chairman, CEO and president of China Sky One Medical, said: “We are very excited about the development of this spray, which serves a huge market in China. We expect to launch the spray in the fourth quarter of 2008, and estimate that sales will add $500,000 to revenue in the fourth quarter.”